Hologicand General Electric Compay.-Notable Market Players in Breast cancer screening Market
Breast cancer screening tests are performed with an aim to analyze the screening of breast cancer. The screening procedure identifies the early signs of cancer, even before the symptoms begin to show. The foremost goal of screening is to detect disease at its earliest and most treatable stage.
Market leaders operating in the market have undertaken various organic growth strategies in the breast cancer screening market. The breast cancer screening market majorly consists of the players such as koninklijke Philips n.v., Hologic, inc.,BD, Myriad Genetics, Inc.,siemens healthcare gmbh, exact sciences corporation Oncocyte Corporation Poc Medical Systems,Danaher,General Electric Among others. Several organic approaches, such as product launches, and expansion/relocation in the breast cancer screening Market, have resulted in the positive growth of the market. Product launches help the company to strengthen its product offering and the customer base, which allows the company to hold a strong position in the market. Similarly, utilizing expansion activities, it is easy to venture into untapped economies and use the opportunities being offered.
Below is the list of the growth strategies done by the players operating in the Breast cancer screening market:
|
Year |
News |
|
Dec-2019 |
GE Healthcare has launched a contrast-enhanced mammography solution namely new Serena Bright, which is claimed to be the healthcare industry’s first contrast-enhanced mammography solution for biopsy |
|
Oct-2018 |
GE Healthcare launched a product namely the Invenia Automated Breast Ultrasound (ABUS) 2.0 in the United States. The device is FDA-approved ultrasound supplemental breast screening technology, specifically designed for detecting cancer in dense breast tissue. |
|
May-2018 |
Siemens Healthineers and ScreenPoint Medical has performed collaboration in designing breast imaging software focused on artificial intelligence. This joint partnership also includes Siemens Healthineers owning a strategic minority interest in ScreenPoint Medical. |
|
Oct-2019 |
Exact Sciences Corp. Acquired the Genomic health. The aquitisition is likely to offer two of the strongest and fastest-growing brands in cancer diagnostics, Cologuard and Oncotype DX. |
